More than money

Abstract

The continually increasing costs of drug development, combined with external financing pressures, have forced a revolution in the contract research industry. Compared to previously when CROs were merely vendors who performed a service in exchange for a fee, today's sponsors increasingly expect a partnership with their CRO - one in which both parties share in the risks and rewards of their drug development endeavours.